OverviewSuggest Edit

    MyoTherix is a drug discovery and development company focusing on therapies for patients suffering from Charcot Marie Tooth disease, Duchenne muscular dystrophy, and other rare neuromuscular disorders. It operates in the biological research industry within the engineering, accounting, research, and management services.

    Latest Updates

    Employees (est.) (Apr 2020)5
    Cybersecurity ratingAMore

    Key People/Management at MyoTherix

    Michael G. Kelly

    Michael G. Kelly

    President & CEO, Director, Co-Founder
    John Kincaid

    John Kincaid

    Director, Co-Founder
    Mark P. de Souza

    Mark P. de Souza

    COO, Director, Co-Founder
    Giles Campion

    Giles Campion

    Chief Medical Officer
    Show more

    MyoTherix Financials and Metrics

    Summary Metrics

    Founding Date


    MyoTherix Cybersecurity Score

    Cybersecurity ratingPremium dataset



    SecurityScorecard logo

    MyoTherix Online and Social Media Presence

    Embed Graph

    MyoTherix Frequently Asked Questions

    • When was MyoTherix founded?

      MyoTherix was founded in 2013.

    • Who are MyoTherix key executives?

      MyoTherix's key executives are Michael G. Kelly, John Kincaid and Mark P. de Souza.

    • How many employees does MyoTherix have?

      MyoTherix has 5 employees.

    • Who are MyoTherix competitors?

      Competitors of MyoTherix include Atara Biotherapeutics, Seneca Biopharma and Synlogic.